Inspire Medical Investors Face Jan. 5 Deadline in Securities Class Action Over Inspire V Rollout

Plaintiffs say Inspire overstated launch readiness for Inspire V, citing billing, training and demand failures that preceded the August 2025 guidance cut.

Overview

Multiple plaintiff firms are urging shareholders to seek lead-plaintiff status before the January 5, 2026 deadline in the pending case.
The suit, filed in the U.S. District Court for the District of Minnesota as City of Pontiac v. Inspire Medical Systems, Inc., No. 0:25-cv-04247, asserts claims under Sections 10(b) and 20(a).
The putative class period runs from August 6, 2024 to August 4, 2025, and no class has been certified.
Complaints allege Inspire failed key launch prerequisites, including timely insurer claims software updates effective only July 1, 2025, completion of training and onboarding at many centers, and adequate demand given excess inventory of older devices.
Inspire disclosed an elongated rollout and cut 2025 EPS guidance by more than 80% on August 4, 2025, after which the stock fell 32% ($42.04) to $87.91, erasing roughly $1.2 billion in market value.